
CLPT Stock Forecast & Price Target
CLPT Analyst Ratings
Bulls say
ClearPoint Neuro Inc has demonstrated a robust growth trajectory, closing 2023 with a 17% increase in topline revenue while significantly reducing cash burn, indicating improved operational efficiency. The company is poised for continued success in 2024, with expectations of at least 20% revenue growth driven by an expanding partnership network and enhanced service offerings in the Biologics segment. Furthermore, recent key product approvals and record system installations, supported by favorable clinical publications, enhance the positive outlook for the company's future financial performance.
Bears say
ClearPoint Neuro has demonstrated a significant reduction in cash burn, decreasing from $5.8 million in the first quarter of 2023 to $1.2 million by the fourth quarter of the same year. Despite this positive trend, the ongoing reliance on cash reserves raises concerns about the company's ability to fund future growth and operations, particularly in a capital-intensive sector. Additionally, an overall negative sentiment may stem from the company's financial stability, underscoring the need for more consistent revenue generation and profitability to support its long-term viability.
This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.
CLPT Analyst Forecast & Price Prediction
Start investing in CLPT
Order type
Buy in
Order amount
Est. shares
0 shares